Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Patients' expression of CEACAM5 might hold the key to activity after all.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.

Claudin18.2 is out, but the US big pharma opts in to a new project.